Cargando…

By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection

In recent years, unprecedented DNA sequencing capacity provided by next generation sequencing (NGS) has revolutionized genomic research. Combining the Illumina sequencing platform and a scFv library designed to confine diversity to both CDR3, >1.9 × 10(7) sequences have been generated. This appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravn, U., Gueneau, F., Baerlocher, L., Osteras, M., Desmurs, M., Malinge, P., Magistrelli, G., Farinelli, L., Kosco-Vilbois, M.H., Fischer, N.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995085/
https://www.ncbi.nlm.nih.gov/pubmed/20846958
http://dx.doi.org/10.1093/nar/gkq789
_version_ 1782193047214227456
author Ravn, U.
Gueneau, F.
Baerlocher, L.
Osteras, M.
Desmurs, M.
Malinge, P.
Magistrelli, G.
Farinelli, L.
Kosco-Vilbois, M.H.
Fischer, N.
author_facet Ravn, U.
Gueneau, F.
Baerlocher, L.
Osteras, M.
Desmurs, M.
Malinge, P.
Magistrelli, G.
Farinelli, L.
Kosco-Vilbois, M.H.
Fischer, N.
author_sort Ravn, U.
collection PubMed
description In recent years, unprecedented DNA sequencing capacity provided by next generation sequencing (NGS) has revolutionized genomic research. Combining the Illumina sequencing platform and a scFv library designed to confine diversity to both CDR3, >1.9 × 10(7) sequences have been generated. This approach allowed for in depth analysis of the library’s diversity, provided sequence information on virtually all scFv during selection for binding to two targets and a global view of these enrichment processes. Using the most frequent heavy chain CDR3 sequences, primers were designed to rescue scFv from the third selection round. Identification, based on sequence frequency, retrieved the most potent scFv and valuable candidates that were missed using classical in vitro screening. Thus, by combining NGS with display technologies, laborious and time consuming upfront screening can be by-passed or complemented and valuable insights into the selection process can be obtained to improve library design and understanding of antibody repertoires.
format Text
id pubmed-2995085
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-29950852010-12-01 By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection Ravn, U. Gueneau, F. Baerlocher, L. Osteras, M. Desmurs, M. Malinge, P. Magistrelli, G. Farinelli, L. Kosco-Vilbois, M.H. Fischer, N. Nucleic Acids Res Methods Online In recent years, unprecedented DNA sequencing capacity provided by next generation sequencing (NGS) has revolutionized genomic research. Combining the Illumina sequencing platform and a scFv library designed to confine diversity to both CDR3, >1.9 × 10(7) sequences have been generated. This approach allowed for in depth analysis of the library’s diversity, provided sequence information on virtually all scFv during selection for binding to two targets and a global view of these enrichment processes. Using the most frequent heavy chain CDR3 sequences, primers were designed to rescue scFv from the third selection round. Identification, based on sequence frequency, retrieved the most potent scFv and valuable candidates that were missed using classical in vitro screening. Thus, by combining NGS with display technologies, laborious and time consuming upfront screening can be by-passed or complemented and valuable insights into the selection process can be obtained to improve library design and understanding of antibody repertoires. Oxford University Press 2010-11 2010-09-15 /pmc/articles/PMC2995085/ /pubmed/20846958 http://dx.doi.org/10.1093/nar/gkq789 Text en © The Author(s) 2010. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/2.5 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methods Online
Ravn, U.
Gueneau, F.
Baerlocher, L.
Osteras, M.
Desmurs, M.
Malinge, P.
Magistrelli, G.
Farinelli, L.
Kosco-Vilbois, M.H.
Fischer, N.
By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection
title By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection
title_full By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection
title_fullStr By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection
title_full_unstemmed By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection
title_short By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection
title_sort by-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection
topic Methods Online
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995085/
https://www.ncbi.nlm.nih.gov/pubmed/20846958
http://dx.doi.org/10.1093/nar/gkq789
work_keys_str_mv AT ravnu bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection
AT gueneauf bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection
AT baerlocherl bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection
AT osterasm bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection
AT desmursm bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection
AT malingep bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection
AT magistrellig bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection
AT farinellil bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection
AT koscovilboismh bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection
AT fischern bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection